The ROE as of December 2024 (TTM) for Inhibrx Biosciences, Inc. (INBX) is 1.45%

According to Inhibrx Biosciences, Inc.’s latest financial reports and current stock price. The company's current ROE is 1.45%. This represents a change of -8027.54% compared to the average of -18.29% of the last 4 quarters.

Inhibrx Biosciences, Inc. (INBX) Historical ROE (quarterly & annually)

How has INBX ROE performed in the past?

The mean historical ROE of Inhibrx Biosciences, Inc. over the last ten years is -99.41%. The current 1.45% ROE has changed -1558.66% with respect to the historical average. Over the past ten years (40 quarters), INBX's ROE was at its highest in in the June 2024 quarter at 846.99%. The ROE was at its lowest in in the March 2024 quarter at -680.41%.

Inhibrx Biosciences, Inc. (INBX) ROE by Quarter and Year

Discovering the peaks and valleys of Inhibrx Biosciences, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Inhibrx Biosciences, Inc. (INBX) Average ROE

How has INBX ROE performed in the past?

The current ROE of Inhibrx Biosciences, Inc. (INBX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Inhibrx Biosciences, Inc. (INBX) ROE vs. Peers

How is INBX’s ROE compared to its peers?

Inhibrx Biosciences, Inc.’s ROE is greater than Crinetics Pharmaceuticals, Inc. (-36.12%), greater than Merus N.V. (-45.38%), greater than Lyell Immunopharma, Inc. (-34.64%), greater than Kronos Bio, Inc. (-64.55%), less than Opthea Limited (398.06%), greater than Mineralys Therapeutics, Inc. (-55.92%), less than Eliem Therapeutics, Inc. (0%), greater than Anebulo Pharmaceuticals, Inc. (-184.40%), greater than Merrimack Pharmaceuticals, Inc. (-35.28%), greater than Celcuity Inc. (-62.66%), greater than Enliven Therapeutics, Inc. (-29.46%), greater than Monte Rosa Therapeutics, Inc. (-62.68%), greater than Design Therapeutics, Inc. (-18.01%), greater than Werewolf Therapeutics, Inc. (-58.83%), greater than Ikena Oncology, Inc. (-39.59%), greater than Stoke Therapeutics, Inc. (-54.45%), less than Protagonist Therapeutics, Inc. (34.68%), less than DICE Therapeutics, Inc. (56.07%), greater than Larimar Therapeutics, Inc. (-35.87%), greater than Viridian Therapeutics, Inc. (-45.47%),

Build a custom stock screener for Inhibrx Biosciences, Inc. (INBX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Inhibrx Biosciences, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Inhibrx Biosciences, Inc. (INBX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Inhibrx Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.